ACIU [NASD]
AC Immune SA
Index- P/E- EPS (ttm)-0.92 Insider Own47.74% Shs Outstand84.46M Perf Week-1.50%
Market Cap231.71M Forward P/E873.33 EPS next Y0.00 Insider Trans0.00% Shs Float43.67M Perf Month-9.50%
Income-77.00M PEG- EPS next Q-0.23 Inst Own18.40% Short Float / Ratio1.02% / 6.38 Perf Quarter-15.48%
Sales4.10M P/S56.52 EPS this Y-13.10% Inst Trans1.10% Short Interest0.45M Perf Half Y-16.56%
Book/sh2.52 P/B1.04 EPS next Y100.00% ROA-32.80% Target Price10.33 Perf Year-48.22%
Cash/sh1.83 P/C1.43 EPS next 5Y- ROE-36.30% 52W Range2.06 - 5.40 Perf YTD-47.07%
Dividend- P/FCF- EPS past 5Y-47.00% ROI- 52W High-51.48% Beta0.53
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low27.18% ATR0.24
Employees143 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)44.79 Volatility9.99% 9.73%
OptionableYes Debt/Eq0.01 EPS Q/Q11.30% Profit Margin- Rel Volume0.00 Prev Close2.62
ShortableYes LT Debt/Eq0.01 EarningsOct 28 BMO Payout- Avg Volume69.72K Price2.62
Recom1.30 SMA20-5.67% SMA50-7.21% SMA200-21.13% Volume0 Change0.00%
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Nov-30-22 07:00AM
Nov-25-22 07:17AM
Nov-23-22 07:30AM
Nov-08-22 07:58AM
Oct-29-22 08:06AM
09:25AM Loading…
Oct-28-22 09:25AM
08:00AM
Oct-04-22 08:36AM
Sep-26-22 07:30AM
Sep-01-22 08:00AM
Aug-24-22 04:05PM
Aug-11-22 07:30AM
Aug-02-22 11:00AM
Jul-31-22 08:12AM
Jul-28-22 08:45AM
07:30AM Loading…
07:30AM
Jul-22-22 07:30AM
Jun-24-22 04:30PM
Jun-21-22 10:35AM
Jun-17-22 08:31AM
Jun-16-22 08:20AM
06:39AM
01:00AM
Jun-01-22 08:26AM
May-31-22 07:30AM
May-17-22 09:00AM
May-09-22 11:00AM
Apr-28-22 07:30AM
Apr-27-22 07:55AM
Apr-08-22 07:30AM
07:58AM Loading…
Mar-30-22 07:58AM
Mar-22-22 07:30AM
Mar-21-22 07:30AM
Mar-16-22 07:41AM
Feb-28-22 07:30AM
Feb-21-22 04:30AM
Feb-15-22 02:54PM
07:30AM
Feb-04-22 07:30AM
Feb-02-22 08:58AM
Dec-15-21 07:49AM
Nov-15-21 06:01AM
Nov-12-21 08:21AM
Nov-10-21 11:20AM
Nov-08-21 08:25AM
07:00AM
Nov-07-21 07:53AM
Nov-05-21 03:00PM
Nov-04-21 06:00AM
Nov-02-21 07:30AM
Oct-29-21 06:00AM
Oct-25-21 07:00AM
Oct-24-21 08:04AM
Sep-03-21 07:52AM
Sep-02-21 07:00AM
Sep-01-21 11:30AM
10:44AM
Aug-31-21 04:03PM
03:40PM
12:13PM
12:05PM
11:06AM
10:22AM
07:59AM
07:30AM
Aug-04-21 08:25AM
07:00AM
Jul-29-21 07:30AM
Jul-28-21 03:03PM
Jul-27-21 09:27AM
08:00AM
07:30AM
Jul-26-21 01:22AM
Jun-25-21 08:38AM
Jun-02-21 07:34AM
07:00AM
May-27-21 01:11AM
May-20-21 07:00AM
May-17-21 09:55AM
07:00AM
Apr-28-21 08:45AM
07:00AM
Apr-20-21 12:00PM
Mar-31-21 07:00AM
Mar-28-21 03:00AM
Mar-26-21 07:00AM
Mar-25-21 01:28AM
Mar-23-21 08:01AM
07:00AM
Mar-16-21 07:00AM
Mar-09-21 07:00AM
Feb-24-21 07:00AM
Feb-17-21 07:00AM
Feb-11-21 08:24PM
04:23PM
08:16AM
07:00AM
Feb-08-21 07:00AM
Jan-29-21 07:00AM
Jan-24-21 01:01AM
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.